HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Free Full Text (PDF) Free Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (9) Citing Articles via Google Scholar Google Scholar Articles by Watters, J. W. Articles by McLeod, H. L. Search for Related Content PubMed PubMed Citation Articles by Watters, J. W. Articles by McLeod, H. L.

MOUSE PHENOME PROJECT

A mouse-based strategy for cyclophosphamide pharmacogenomic discovery

Departments of ¹Medicine, ²Dermatology, ⁵Genetics, and ⁴Molecular Biology and Pharmacology, Washington University School of Medicine, and ³The Siteman Cancer Center, St. Louis, Missouri 63110

Submitted 3 March 2003 ; accepted in final form 10 April 2003

ABSTRACT

Genome-wide mapping approaches are needed to more fully understand the genetic basis of chemotherapy response. Because of technical and ethical limitations, cancer pharmacogenomics has not yet benefited from traditional robust familial genetic strategies. We have therefore explored the use of the inbred mouse as a genetic model system in which to study response to the cytotoxic agent cyclophosphamide. Multiple phenotypes have been assessed in response to cyclophosphamide in up to 19 inbred mouse strains, including in vitro hematopoietic progenitor cell toxicity and the mobilization of hematopoietic progenitor cells into peripheral blood. Hematopoietic progenitor cell toxicity in vitro varied 2-fold among strains, whereas in vivo progenitor cell mobilization varied almost 75-fold among strains. Males mobilized more hematopoietic progenitor cells than did females, and the low-mobilization phenotype was dominant to the high-mobilization phenotype in F1 hybrid animals. In an initial attempt to analyze candidate genes, genetic variation was assessed in three cytochrome P-450 genes involved in the metabolism of cyclophosphamide. Resequencing of eight strains identified 26 polymorphisms in these genes that may influence response to cyclophosphamide. Distinct regions of high- and low-polymorphism rates were identified, and two common haplotypes were shared among the strains for each gene that exhibited variation. This phenotypic and genotypic variation among inbred strains provides a framework for cyclophosphamide pharmacogenomic discovery.

pharmacogenetics; mobilization

This article has been cited by other articles:

				U. Emmenegger, Y. Shaked, S. Man, G. Bocci, I. Spasojevic, G. Francia, A. Kouri, R. Coke, W. Cruz-Munoz, S. M. Ludeman, et al. Pharmacodynamic and pharmacokinetic study of chronic low-dose metronomic cyclophosphamide therapy in mice Mol. Cancer Ther., August 1, 2007; 6(8): 2280 - 2289. [Abstract] [Full Text] [PDF]

				V. Y. Gorbacheva, R. V. Kondratov, R. Zhang, S. Cherukuri, A. V. Gudkov, J. S. Takahashi, and M. P. Antoch From The Cover: Circadian sensitivity to the chemotherapeutic agent cyclophosphamide depends on the functional status of the CLOCK/BMAL1 transactivation complex PNAS, March 1, 2005; 102(9): 3407 - 3412. [Abstract] [Full Text] [PDF]

				M. Bogue Mouse Phenome Project: understanding human biology through mouse genetics and genomics J Appl Physiol, October 1, 2003; 95(4): 1335 - 1337. [Full Text] [PDF]